Allozyne Analysis: $34M Raised
What is Allozyne?
Allozyne develops and commercializes technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Their PEGylated IFN beta is specifically designed for the treatment of multiple sclerosis. Founded in 2005, Allozyne is based in Seattle, Washington.
Location
1600 Fairview Ave E, Seattle, Washington 98102, United States
Employees
11-50
Founded
2005
Product Features & Capabilities
- PEGylated IFN beta for multiple sclerosis treatment
Use Cases
Enhance efficacy of protein therapeutics; Improve safety profiles of biologics; Optimize dosing regimens for therapeutic proteins; Develop vaccines with improved characteristics; Support research in protein-based drug development
How much Allozyne raised
Funding - $34M
Other Considerations
Acquired by MedImmune; Active in the biotechnology sector; Focused on therapeutics for healthcare
See something that needs updating? Suggest edits to this profile.